Hemant Kumar Vyas PhD
About Hemant Kumar Vyas PhD
Hemant Kumar Vyas, PhD, is an Associate Director at Alkermes and a Senior Manager of Medical Communications at uniQure, with extensive experience in biotech and pharmaceutical industries.
Current Roles at uniQure and Alkermes
Hemant Kumar Vyas, PhD, is serving in dual roles at two prominent organizations in the Massachusetts area. Currently, he holds the position of Senior Manager of Medical Communications at uniQure in Lexington. Concurrently, he also works as an Associate Director at Alkermes in Waltham.
Past Work Experience at TESARO and Texas Biomedical Research Institute
Dr. Vyas has held the role of Manager at TESARO, Inc. from 2017 to 2019, working in Waltham, MA. Prior to this, he was a Postdoctoral Research Scientist VI at Texas Biomedical Research Institute in San Antonio, Texas from 2013 to 2017. These roles have added substantial depth to his experience in the biomedical research sector.
Earlier Research Positions at Dana-Farber Cancer Institute and Harvard Medical School
Hemant Kumar Vyas, PhD, worked as a Research Fellow at Dana-Farber Cancer Institute and a Postdoctoral Associate at Harvard Medical School from 2010 to 2013 in Boston. These positions solidified his expertise in both clinical and basic research communications.
Academic Background and Early Career
Dr. Vyas began his academic journey by earning a B.Sc. in Agricultural Sciences from Rajasthan Agricultural University, followed by an M.Sc. in Biotechnology from the same institution. He then completed his PhD in Life Sciences at the University of Rajasthan. His postgraduate research also includes time spent at the National Institute of Immunology in India, where he worked in the Immuno Endocrinology Laboratory and Bio-organic Chemistry Laboratory.
Expertise in Immunoconjugates and Antibody Development
Experienced in developing immunoconjugates and bispecific antibodies, Dr. Vyas has strong skills in single B cell sorting and generating high-affinity monoclonals. His work has also contributed to the development of antibody-based therapeutics and vaccine development. He is proficient in managing relationships with key opinion leaders and operating in a matrix environment for scientific communications.